Table 2 Logistic regression analyses of the incidence of pegfilgrastim-induced bone pain

Sex

 Male

2 (3)

Reference

Reference

 Female

28 (12)

5.54

1.29–23.83

0.021

1.909

0.35–10.16

0.455

Age

 < 55 years

21 (20)

5.31

2.32–12.07

 > 0.001

3.62

1.51–8.69

0.004

 ≥ 55 years

9 (5)

Reference

Reference

Pre-existing osteoporosis

 Yes

0

NA

-

 No

30 (10)

NA

-

Type of tumor

 Solid cancers

27 (14)

5.39

1.60–18.21

0.007

2.52

0.62–10.19

0.194

 Hematologic cancers

3 (3)

Reference

Reference

Bone metastasis

 Present

3 (10)

0.71

0.21–4.84

0.596

-

 Absent

27 (10)

Reference

-

Opioids

 Yes

1 (8)

0.79

0.09–6.02

0.784

-

 No

29 (10)

Reference

-

NSAIDs

 Yes

2 (13)

1.33

0.28–6.16

0.714

-

 No

28 (10)

Reference

-

Prior chemotherapy

 Yes

4 (14)

1.61

0.52–4.99

0.412

-

 No

26 (9)

Reference

-

Type of chemotherapy

 Adjuvant chemotherapy

21 (14)

2.93

1.29–6.62

0.010

-

 Chemotherapy alone

9 (6)

Reference

-

Type of prophylaxis

 Primary

23 (9)

1.48

0.60–3.64

0.410

 Secondary

7 (13)

Reference

Pegfilgrastim injection

 Days 2 or 3

10 (8)

Reference

-

 Days 4–7

20 (11)

1.53

0.69–3.38

0.298

-